About Auxogyn Board of Directors
Beth joined Kleiner Perkins Caufield & Byers in May 2005 to work in the life sciences area. She is currently on the Board of Directors of 3-V Biosciences, Arresto Biosciences, BioCryst Pharmaceuticals, Breathe Technologies, Epizyme, iPierian, Inc, and RedBrick Health. Her primary focus is in novel therapeutics to treat unmet medical needs.
Beth was formerly the Senior Vice President, Global Development, and Chief Medical Officer at Amgen. Prior to joining Amgen, Beth was a senior executive in research and development at Bristol-Myers Squibb and Merck & Co. She began her career in basic and clinical research at the National Institutes of Health specializing in immunology and infectious diseases. In total, she introduced 10 innovative products to market and achieved over 40 regulatory approvals (including new indications and formulations) on a worldwide basis.
Beth received her B.S. from Barnard College and her medical degree from the University Of Miami School Of Medicine. Her post-graduate training was completed at Johns Hopkins and the National Institutes of Health.
Prior to joining TPG Biotech in 2008, Mark Gudiksen was an Engagement Manager in McKinsey & Company’s west coast healthcare practice. At McKinsey, he worked on a broad spectrum of strategic topics and M&A opportunities with a variety of clients, including biopharmaceutical & medical device companies, hospital chains, and private equity firms.
Mark received his Ph.D. in chemical physics from Harvard, and his B.S. in chemistry from Stanford. Mark’s doctoral work in nanotechnology was recognized with several highly cited publications in leading scientific journals, such as Science and Nature, as well as general audience publications as broad as Scientific American and the Wall Street Journal. In addition to serving on the board of directors of Auxogyn, Inc., Mark is also a board observer for Nodality, Inc.
Lissa Goldenstein is a co-founder of Auxogyn and has more than seven years experience as President and CEO of both public and private companies in the life science industry. Most recently Lissa served as President and CEO of Artemis Health, Inc., a venture backed company focused on developing non-invasive prenatal diagnostic tests, where she defined the business strategy, broadened the product and intellectual property portfolio and secured more than $20 million in funding over a three year period. Prior to Artemis Health, Lissa served as President and CEO of Argonaut Technologies, Inc. (NASDAQ; AGNT) from 2001 until June 2005, at which time Argonaut’s assets were sold to Biotage, AB. Argonaut was the leading provider of consumables, instruments and services that enable chemists in the pharmaceutical industry to accelerate and improve the development of new drugs. Prior to that Lissa had more than 20 years of worldwide sales, marketing, and service experience bringing new technology to new markets in both the life science and engineering industries.
Lissa has a B.S. in Architectural Engineering from Pennsylvania State University and received her Professional Engineers license as a structural engineer in the State of California. Lissa is currently on the Board of Directors of Argonaut Technologies and was on the Board of Directors for OtisMed Corporation until its recent acquisition it was recently acquired by Stryker Corporation.
Renee Reijo Pera is the Director of the Stanford University Center for Human Embryonic Stem Cell Research and Education, Director of Basic and Translational Research in Women’s Health at Stanford, a founding member of the Stanford Institute for Stem Cell Biology & Regenerative Medicine, and a Professor of Obstetrics and Gynecology. She is a co-founder of The Stem Cell Advisors, Inc, a public benefit corporation that provides consulting services, training programs, research and clinical trial oversight for stem cell applications. She also serves as Adjunct Professor in the Kyoto Center for iPS Cell Research and Application (CIRA). Her research has led to identification of the first human "infertility gene," discovery of the unique gene expression profiles of human embryos during the first few days of development, and the first differentiation of mature human germ cells (cells which give rise to eggs and sperm) in vitro from pluripotent human stem cells.
Renee has received numerous awards throughout her career including Outstanding Faculty Mentor (2005) and one of the 20 Top Women On Leadership in the United States as featured in Newsweek 2006. She received her Bachelor of Science degree from the University of Wisconsin (Superior), her doctoral degree from Cornell University in Ithaca, New York, and her postdoctoral training at the Whitehead Institute for BioMedical Research at the Massachusetts Institute of Technology in Cambridge, Massachusetts.
